The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Hormone Receptor Status, Treatment, and Outcomes in Metastatic Breast Cancer.
 
Kazuto Harada
No Relationships to Disclose
 
Carol C Wu
Patents, Royalties, Other Intellectual Property - Royalties for authorship from Elsevier Inc
 
Xuemei Wang
No Relationships to Disclose
 
Dilsa Mizrak Kaya
No Relationships to Disclose
 
Fatemeh Ghazanfari Amlashi
No Relationships to Disclose
 
Quan Lin
No Relationships to Disclose
 
Mariela A. Blum Murphy
Honoraria - EMD Serono
Research Funding - AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst)
 
Dipen M. Maru
No Relationships to Disclose
 
Brian Weston
No Relationships to Disclose
 
Jeffrey H Lee
Honoraria - Boston Scientific
Consulting or Advisory Role - Boston Scientific
Research Funding - Olympus
Travel, Accommodations, Expenses - Boston Scientific
 
Manoop S. Bhutani
No Relationships to Disclose
 
Wayne Lewis Hofstetter
No Relationships to Disclose
 
Quynh Nguyen
No Relationships to Disclose
 
Jaffer A. Ajani
Honoraria - Bayer; Five Prime Therapeutics; Genentech; Lilly/ImClone; Novartis; Roche/Genentech; Taiho Pharmaceutical
Research Funding - Amgen; Bristol-Myers Squibb; Delta-Fly Pharma; Gilead Sciences; Lilly/ImClone; MedImmune; Merck; Novartis; Roche/Genentech; Taiho Pharmaceutical; Takeda
Patents, Royalties, Other Intellectual Property - I have research funding from: Genentech, Roche, BMS, Taiho, MedImmune, Merck, Amgen, Lilly
Travel, Accommodations, Expenses - Bayer; Five Prime Therapeutics; Novartis